29 November 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Change of Auditor

Diaceutics PLC, (AIM: DXRX), a leading diagnostic commercialisation company which provides data, analytics and technology enabled services via its proprietary DXRX platform to the Precision Medicine market announces that, following the conclusion of a formal tender process led by the Company's Audit Committee, the Board has approved the proposed appointment of Ernst & Young ("EY") as the Company's auditor for the financial year ending 31 December 2022. A proposal to re-appoint EY will be subject to approval by the Company's shareholders at the next Annual General Meeting to be held in 2023.

PricewaterhouseCoopers LLP, the Company's current auditor, has resigned and has confirmed that there are no matters connected with it ceasing to hold office that should be brought to the attention of the members or creditors of the Company. 

Enquiries:

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.